Bristol-Myers $450M Payment Dispute Heads To Arbitration

By Editorial Team

A recent development in Delaware’s Court of Chancery has seen allegations from shareholders of a small biotechnology company acquired by Bristol-Myers Squibb being sent to arbitration. The shareholders claim that the pharmaceutical giant engaged in deceptive practices to avoid making milestone payments amounting to $450 million.

The dispute revolves around Bristol-Myers Squibb’s acquisition of the biotechnology company and the subsequent failure to make the agreed-upon milestone payments. The case has now been referred to arbitration to address the allegations of trickery and non-compliance with payment obligations.

Legal experts are closely monitoring the case as it progresses through the arbitration process. The involvement of notable law firms such as Abrams & Bayliss, Dechert LLP, Jones Day, and Richards Layton underscores the significance of the dispute.

Key entities involved in the case include Bristol-Myers Squibb Co., the biotechnology company Therapeutics Inc., and the Delaware Court of Chancery overseeing the proceedings.

As the dispute heads to arbitration, stakeholders await further developments to determine the outcome of the $450 million payment dispute between Bristol-Myers Squibb and the shareholders of the biotechnology company.